Please wait while the formulary information is being retrieved.
VECURONIUM BROMIDE (vecuronium bromide)
- General anesthesia adjunct
- Skeletal muscle relaxation for endotracheal intubation
- Muscle relaxation
10 mg intravenous solution
- Infuse 1 mcg/kg/minute by continuous infusion route
20 mg intravenous solution
- Infuse 1 mcg/kg/minute by continuous infusion route
10 mg intravenous solution
- Infuse 1 mcg/kg/minute by continuous infusion route
20 mg intravenous solution
- Infuse 1 mcg/kg/minute by continuous infusion route
Muscle relaxation
- Infuse 1 mcg/kg/minute by continuous infusion route
- None
Contraindicated
- Adoxa
- amikacin
- Avidoxy
- Calan
- Calan Sr
- Compound 347
- demeclocycline
- dextromethorphan-quinidine
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- enflurane
- Forane
- gentamicin
- gentamicin in NaCl (iso-osm)
- gentamicin sulfate (ped) (PF)
- gentamicin sulfate (PF)
- isoflurane
- Minocin
- minocycline
- Monodox
- Morgidox
- neomycin
- Nuedexta
- Oracea
- paromomycin
- Qualaquin
- quinidine gluconate
- quinidine sulfate
- quinine sulfate
- sevoflurane
- Sojourn
- Solodyn
- streptomycin
- Tarka
- Terrell
- tetracycline
- tigecycline
- tobramycin in 0.9 % NaCl
- tobramycin sulfate
- trandolapril-verapamil
- Tygacil
- Ultane
- verapamil
- Verelan
- Verelan Pm
- Vibramycin
Severe
Moderate
- Acanya
- Baciim
- bacitracin
- Benzaclin
- Benzaclin Pump
- Capastat
- capreomycin
- Cerebyx
- Cleocin
- Cleocin In 5 % Dextrose
- Cleocin T
- Clindacin Etz
- Clindacin P
- Clindacin Pac
- Clindagel
- clindamycin HCl
- clindamycin in dextrose 5%
- clindamycin palmitate HCl
- Clindamycin Pediatric
- clindamycin phos-skin clnsr 19
- clindamycin phosphate
- clindamycin-benzoyl peroxide
- clindamycin-tretinoin
- Clindesse
- colistin (colistimethate Na)
- Coly-mycin M Parenteral
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Duac
- ethotoin
- Evoclin
- fosphenytoin
- Hyperlyte Cr
- Lincocin
- lincomycin
- magnesium chloride
- magnesium sulfate
- magnesium sulfate in D5W
- Nutrilyte Ii
- Peganone
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- piperacillin-tazobactam
- piperacillin-tazobactam-dextrs
- polymyxin B sulfate
- sodium-K+-mag-Ca-chlor-acetate
- Tpn Electrolytes
- Tpn Electrolytes Ii
- vancomycin
- vancomycin in D5W
- vancomycin in dextrose iso-osm
- Veltin
- Ziana
- Zosyn
- Zosyn In Dextrose (iso-osm)
- None
Contraindicated
- Eaton-lambert syndrome
- Myasthenia gravis
Severe
Moderate
- Cholestasis
- Hepatic cirrhosis
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Morbid obesity
- Neuromuscular disease
VECURONIUM BROMIDE (vecuronium bromide)
- General anesthesia adjunct
- Skeletal muscle relaxation for endotracheal intubation
- Muscle relaxation
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Anaphylaxis
- Bradycardia
- Bronchospastic pulmonary disease
- Cardiogenic shock
- Circulatory depression
- Edema
- Erythema
- Flushing
- Hypotension
- Pruritus of skin
- Skin rash
- Tachycardia
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Vecuronium
Safety and efficacy not established age < 7 weeks. Infants more sensitive to effects.
Increased sensitivity to effects, larger volume of distribution. Longer recovery time possible.
- 1 Day – 48 Days
- Safety and efficacy not established age < 7 weeks. Infants more sensitive to effects.
- Increased sensitivity to effects, larger volume of distribution. Longer recovery time possible.
- 49 Days – 364 Days
- Safety and efficacy not established age < 7 weeks. Infants more sensitive to effects.
- Increased sensitivity to effects, larger volume of distribution. Longer recovery time possible.
Vecuronium Bromide
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Vecuronium Bromide
Excretion unlikely due to short elimination half-life & low lipid solubility
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Excretion unlikely due to short elimination half-life & low lipid solubility |
Contraindicated
None
Precaution Exists
Vecuronium
General-Geriatrics may have delay in onset time and longer lasting pharmacological effect. Higher doses to overcome delay in onset time are not recommended.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Formulary Reference Tool